文献速递神经肿瘤

立体定向放射外科治疗放射性脑膜瘤的长期结局与荟萃分析

Stereotactic radiosurgery for radiation‑induced meningiomas: long‑term institutional outcomes with patient- and lesion‑level analyses and an updated meta‑analysis.
PubMed 文献 · J Neurooncol · 2025-12-15

单中心回顾性分析9例患者25个放射性脑膜瘤病灶接受单次立体定向放射外科(SRS)治疗,中位随访61个月,1年和5年局部控制率分别为92%和76%,5年无进展生存率为78%,无超过3级毒性。对四项已发表系列(110例患者、212个病灶)的荟萃分析显示,汇总5年局部控制率为78%(95%CI 69–85)。

要点

  • 放射性脑膜瘤SRS治疗后5年局部控制率约76%–78%,无进展生存率72%–78%。
  • 病灶≥20 mm时局部控制率降至58%,应优先考虑手术切除。
  • SRS毒性低,本组无超过3级不良事件,汇总毒性为12%(95%CI 9–17)。

核心结论

  • SRS可为多数放射性脑膜瘤提供持久的肿瘤控制且并发症发生率低,但病灶≥20 mm时疗效较低,应优先选择手术切除。
  • 汇总5年局部控制率接近80%,研究间异质性主要来自队列规模和随访时长。

研究设计与样本

  • 单中心回顾性研究,纳入2002–2025年接受单次SRS治疗的放射性脑膜瘤患者9例、病灶25个。
  • 25个病灶中9个有组织病理(5个WHO 1级、4个WHO 2级),其余为影像学诊断。
  • 同时进行系统综述与随机效应荟萃分析,汇总四项已发表系列(110例患者、212个病灶)。

主要发现

  • 中位年龄40岁,潜伏期29年,中位剂量15 Gy(范围13–15 Gy),中位随访61个月。
  • 1年和5年局部控制率分别为92%和76%,5年无进展生存率为78%。
  • 局部控制率随肿瘤增大而下降:<10 mm为100%,10–<15 mm为94%,15–20 mm为83%,≥20 mm为58%(log-rank p = .04)。
  • 本组无患者出现超过3级毒性。
  • 汇总分析:5年局部控制率78%(95%CI 69–85),无进展生存率72%(95%CI 63–79),总毒性12%(95%CI 9–17);合并队列后汇总5年局部控制率为77%(95%CI 70–84)。

关键数值与推荐

  • 单次SRS中位剂量15 Gy(范围13–15 Gy),依据病灶与关键神经血管结构的邻近关系选择。
  • 病灶<10 mm局部控制率100%,10–<15 mm为94%,15–20 mm为83%,≥20 mm为58%(log-rank p = .04)。
  • 汇总四项系列5年局部控制率78%(95%CI 69–85)、无进展生存率72%(95%CI 63–79)、总毒性12%(95%CI 9–17)。
  • 合并本组与文献队列后汇总5年局部控制率77%(95%CI 70–84)。

临床怎么用

  • 对体积较小、邻近关键神经血管结构的放射性脑膜瘤,单次SRS是可行的微创选择。
  • 病灶≥20 mm时局部控制率明显下降,应优先考虑手术切除。
  • 需规范毒性报告并建立前瞻性登记以完善长期风险模型。

局限性

  • 单中心回顾性设计,样本量小(9例患者、25个病灶),仅9个病灶有组织病理。
  • 部分病灶为影像学诊断,缺乏病理确诊。
  • 荟萃分析纳入研究间存在异质性,主要与队列规模和随访时长有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation-induced meningiomas (RIMs) are late sequelae of cranial irradiation that are often multifocal, atypical, and surgically challenging. Stereotactic radiosurgery (SRS) is a minimally invasive treatment alternative, but long-term outcomes have not been described fully. METHODS: All patients with RIM treated with single-fraction SRS at a single tertiary care center (2002–2025) were reviewed for lesion-level local control (LC), progression-free survival (PFS), and toxicity graded by Common Terminology Criteria for Adverse Events v5.0 criteria. Histopathology was available for 9 of 25 lesions (5 WHO grade 1, 4 WHO grade 2); the remainder were diagnosed radiographically. We also conducted a systematic review and random-effects meta-analysis. RESULTS: Among 9 patients with 25 lesions, median age was 40 years, latency was 29 years, and median dose was 15 Gy (range 13–15 Gy), selected based on proximity to critical neurovascular structures. Median follow-up was 61 months; 1- and 5-year LC were 92% and 76%, respectively. LC declined with larger tumors (100% for < 10 mm, 94% for 10–<15 mm, 83% for 15–20 mm, and 58% for ≥ 20 mm; log-rank p = .04). Five-year PFS was 78%. No patients experienced toxicity greater than grade 3. Across four published series (110 patients with 212 lesions), pooled 5-year LC was 78% (95% confidence interval (CI) 69–85), PFS was 72% (95% CI 63–79), and overall toxicity was 12% (95% CI 9–17). Combining these cohorts yielded a pooled 5-year LC rate of 77% (95% CI 70–84). CONCLUSIONS: SRS and fractionated SRS provide durable tumor control for most RIMs with low morbidity. Efficacy is lower for lesions ≥ 20 mm, and resection should be prioritized. Pooled 5-year LC approaches 80%, with between-study heterogeneity largely driven by cohort size and follow-up duration. Standardized toxicity reporting and prospective registries are needed to refine long-term risk modeling.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Jhandi S, Jhandi AS, Cannon DM, et al. Stereotactic radiosurgery for radiation‑induced meningiomas: long‑term institutional outcomes with patient- and lesion‑level analyses and an updated meta‑analysis. J Neurooncol. 2025. PMID: 41396461. doi:10.1007/s11060-025-05376-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。